Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | WDR5 | P61964 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14660788 | 1.00 | SIRT6 (0.50) | SIRT6ALDH1A1SMN1; SMN2LMNAWDR5 | |
| SCHEMBL20680880 | 0.87 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2LMNAMAPTCYP2C9 | |
| SCHEMBL29974407 | 0.87 | SIRT6 (0.46) | SIRT6ALDH1A1SMN1; SMN2LMNAWDR5 | |
| SCHEMBL16668618 | 0.87 | SIRT6 (0.46) | SIRT6ALDH1A1SMN1; SMN2LMNAWDR5 | |
| SCHEMBL14718433 | 0.86 | SIRT6 (0.51) | SIRT6ALDH1A1SMN1; SMN2LMNAWDR5 | |
| SCHEMBL18902052 | 0.85 | SIRT6 (0.47) | SIRT6ALDH1A1SMN1; SMN2LMNAWDR5 | |
| SCHEMBL14660716 | 0.82 | SIRT6 (0.53) | SIRT6ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL21816659 | 0.81 | MEN1 (0.47) | ALDH1A1SMN1; SMN2LMNACYP1A2MAPK1 | |
| SCHEMBL29929807 | 0.79 | EGFR (0.49) | SIRT6ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL13832430 | 0.78 | SIRT6 (0.49) | SIRT6ALDH1A1SMN1; SMN2WDR5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182441-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2024-06-06 | — | — | US | disclosed |
| EP-4119551-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | Astrazeneca AB (SE) | 2023-01-18 | — | — | EP | disclosed |
| US-11524951-B2 | 2-(2,4,5-substituted-anilino)pyrimidine compounds | ASTRAZENECA AB (SE) | 2022-12-13 | — | — | US | disclosed |
| US-20210130318-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2021-05-06 | — | — | US | disclosed |
| US-10858336-B2 | 2-(2,4,5-substituted-anilino)pyrimidine compounds | ASTAZENECA AB (SE) | 2020-12-08 | — | — | US | disclosed |
| EP-3686194-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | Astrazeneca AB (SE) | 2020-07-29 | — | — | EP | disclosed |
| EP-3686193-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | Astrazeneca AB (SE) | 2020-07-29 | — | — | EP | disclosed |
| EP-3333161-B1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2020-02-19 | — | — | EP | disclosed |
| US-20190092746-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2019-03-28 | — | — | US | disclosed |
| US-10017493-B2 | 2-(2,4,5-substituted-anilino)pyrimidine compounds | ASTRAZENECA AB (SE) | 2018-07-10 | — | — | US | disclosed |
| EP-3333161-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | Astrazeneca AB (SE) | 2018-06-13 | — | — | EP | disclosed |
| EP-3009431-B1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2017-10-25 | — | — | EP | disclosed |
| US-9732058-B2 | 2-(2,4,5-substituted-anilino)pyrimidine compounds | ASTRAZENECA AB (SE) | 2017-08-15 | — | — | US | disclosed |
| EP-3009431-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | Astrazeneca AB (SE) | 2016-04-20 | — | — | EP | disclosed |
| EP-2736895-B1 | 2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2016-01-06 | — | — | EP | disclosed |
| US-20150119379-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2015-04-30 | — | — | US | disclosed |
| US-8946235-B2 | 2-(2,4,5-substituted-anilino) pyrimidine compounds | ASTRAZENECA AB (SE) | 2015-02-03 | — | — | US | disclosed |
| EP-2736895-A1 | 2 - (2, 4, 5 - SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | Astrazeneca AB (SE) | 2014-06-04 | — | — | EP | disclosed |
| US-20130053409-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2013-02-28 | — | — | US | disclosed |
| WO-2013014448-A1 | 2 - (2, 4, 5 - SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2013-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053409-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | SIRT6 3423/4885ALDH1A1 2153/4885SMN1; SMN2 2671/4885 |
| US-20190092746-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | SIRT6 3423/4885ALDH1A1 2153/4885SMN1; SMN2 2671/4885 |
| US-20210130318-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | SIRT6 3423/4885ALDH1A1 2153/4885SMN1; SMN2 2671/4885 |
| US-10017493-B2 | 2-(2,4,5-substituted-anilino)pyrimidine compounds | EGFR, ERBB2, ERBB3 | SIRT6 3423/4885ALDH1A1 2153/4885SMN1; SMN2 2671/4885 |
| US-10858336-B2 | 2-(2,4,5-substituted-anilino)pyrimidine compounds | EGFR, ERBB2, ERBB3 | SIRT6 3423/4885ALDH1A1 2153/4885SMN1; SMN2 2671/4885 |
| US-20150119379-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | SIRT6 3423/4885ALDH1A1 2153/4885SMN1; SMN2 2671/4885 |
| US-11524951-B2 | 2-(2,4,5-substituted-anilino)pyrimidine compounds | EGFR, ERBB2, ERBB3 | SIRT6 3423/4885ALDH1A1 2153/4885SMN1; SMN2 2671/4885 |
| US-20240182441-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | SIRT6 3423/4885ALDH1A1 2153/4885SMN1; SMN2 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.